TY - JOUR ID - 10769 TI - Feasibility of high-dose iodine-131-metaiodobenzylguanidine therapy for high-risk neuroblastoma preceding myeloablative chemotherapy and hematopoietic stem cell transplantation: a study protocol JO - Asia Oceania Journal of Nuclear Medicine and Biology JA - AOJNMB LA - en SN - 2322-5718 AU - Araki, Raita AU - Nishimura, Ryosei AU - Inaki, Anri AU - Wakabayashi, Hiroshi AU - Imai, Yasuhito AU - Kuribayashi, Yoshikazu AU - Yoshimura, Kenichi AU - Murayama, Toshinori AU - Kinuya, Seigo AD - Department of Pediatrics, School of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Japan AD - Department of Nuclear Medicine, School of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Japan AD - Innovative Clinical Research Center, Kanazawa University, Japan Y1 - 2018 PY - 2018 VL - 6 IS - 2 SP - 161 EP - 166 KW - 131I-MIBG KW - Neuroblastoma KW - Hematopoietic stem cell transplantation KW - Prospective study protocol DO - 10.22038/aojnmb.2018.29845.1203 N2 - Objective(s): High-risk neuroblastoma is a childhood cancer with poorprognosis despite modern multimodality therapy. Internal radiotherapy using131I-metaiodobenzylguanidine (MIBG) is effective for treating the disease even if it isresistant to chemotherapy. The aim of this study is to evaluate the safety and efficacyof 131I-MIBG radiotherapy combined with myeloablative high-dose chemotherapyand hematopoietic stem cell transplantation.Methods: Patients with high-risk neuroblastoma will be enrolled in this study. A totalof 8 patients will be registered. Patients will receive 666 MBq/kg of 131I-MIBG andafter safety evaluation will undergo high-dose chemotherapy and hematopoietic stemcell transplantation. Autologous and allogeneic stem cell sources will be accepted.After engraftment or 28 days after hematopoietic stem cell transplantation, the safetyand response will be evaluated.Conclusion: This is the first prospective study of 131I-MIBG with high-dosechemotherapy and hematopoietic stem cell transplantation in Japan. The results willbe the basis of a future nationwide clinical trial. UR - https://aojnmb.mums.ac.ir/article_10769.html L1 - https://aojnmb.mums.ac.ir/article_10769_d6ef75df32736d417d90d27453c3750d.pdf ER -